The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Is The Krystexxa Market’s Market Value Anticipated To Evolve From 2026 To 2030?
Historically, this expansion was driven by the inherent constraints of traditional gout treatments, the escalating occurrence of chronic gout, the clinical achievements of pegloticase, a rise in co-existing medical conditions, and the growing presence of specialized rheumatology practices.
The anticipated growth throughout the forecast period is attributed to a growing number of patients with refractory gout, an increase in referrals to specialty clinics, the expansion of infusion services, supportive reimbursement policies for biologics, and a continued unmet need in severe gout. Key trends for the forecast period include the increasing adoption of biologic therapies for refractory gout, a focus on treatments involving uric acid-lowering enzymes, the specialized management of chronic gout patients, the broadening of infusion-based rheumatology care, and a rising utilization in severe and treatment-resistant cases.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20134&type=smp
What Market Drivers Are Helping Shape The Krystexxa Market Expansion?
The rising occurrence of gout disease is anticipated to drive the expansion of the Krystexxa market in the future. Gout is an arthritis condition resulting from the accumulation of uric acid crystals within joints, causing inflammation, discomfort, and swelling. This heightened incidence of gout is linked to various elements, including inadequate dietary practices, excess weight, advancing age, specific drugs, hereditary factors, long-term kidney dysfunction, inactive living, and co-existing ailments such as hypertension and diabetes. Krystexxa (pegloticase) assists individuals with gout by decreasing blood uric acid concentrations, particularly addressing persistent gout unresponsive to standard therapies, thus lessening the occurrence and intensity of gout attacks and alleviating the distressing symptoms of the ailment. As an illustration, in June 2024, Rheumatology and Therapy, an international peer-reviewed medical journal based in the US, reported that the combined prevalence of gout and chronic kidney disease in the United States was forecast to climb from 7.9 million in 2023 to 8.6 million in 2027, subsequently to 9.2 million in 2031, and ultimately reaching 9.6 million in 2035, indicating a 29% rise between 2023 and 2035. Consequently, the growing frequency of gout disease is propelling the Krystexxa market.
Which Segment Divisions Form The Structure Of The Krystexxa Market?
The krystexxa market covered in this report is segmented –
1) By Formulation: Injectable Formulation (Lyophilized Powder), Ready-To-Use Solutions
2) By Indication: Treatment Of Chronic Gout, Management Of Hyperuricemia In Gout Patients, Treatment Of Refractory Gout
3) By Patient Demographics: Adult Patients, Elderly Patients, Patients With Comorbid Conditions
4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals, Specialty Clinics, Rheumatology Practices, Home Healthcare Providers
What Trends Are Driving Changes In The Krystexxa Market?
A significant trend in the Krystexxa market involves the advancement of immunomodulatory strategies, such as the rheumatology research dissemination initiative, aimed at improving the visibility of clinical evidence, facilitating informed therapeutic choices, and enhancing stakeholder comprehension of emerging developments in inflammatory and autoimmune disease management. This initiative constitutes a structured approach to scientific communication, designed to present, share, and advance new clinical findings, therapeutic data, and investigational insights within the field of rheumatology. For instance, in June 2024, Amgen Inc., a US-based biotechnology company, showcased cutting-edge rheumatology research during the European Alliance of Associations for Rheumatology (EULAR) 2024 Congress, bringing forth novel clinical data pertaining to Krystexxa (pegloticase). This research revealed broader insights into treatment response patterns, patient-reported outcomes, and immunologic behavior when using advanced therapeutic combinations. Krystexxa, a PEGylated uricase enzyme therapy, persists in exhibiting distinct clinical advantages for adults with uncontrolled chronic gout by leveraging precision immune modulation to improve efficacy and manage anti-drug antibody formation. The fresh data presented by Amgen further solidifies Krystexxa’s position as a leading biologic option for patients with severe gout who have not responded adequately to conventional therapies.
Which Companies Form The Competitive Landscape Of The Krystexxa Market?
Major companies operating in the krystexxa market are Amgen Inc.
Access The Complete Krystexxa Market Report:
https://www.thebusinessresearchcompany.com/report/krystexxa-global-market-report
Which Region Is The Primary Market For The Krystexxa Market?
North America was the largest region in the krystexxa market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the krystexxa market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model